ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.

Autor:	Heravi M; Department of Human Genetics, McGill University, Montreal, Canada; Department of Radiation Oncology, McGill University, Montreal, Canada; Segal Cancer Center, Jewish General Hospital, Montreal, Canada., Kumala S; Department of Radiation Oncology, McGill University, Montreal, Canada; Segal Cancer Center, Jewish General Hospital, Montreal, Canada., Rachid Z; Cancer Drug Research Laboratory, McGill University Health Center, Montreal, Canada., Jean-Claude BJ; Cancer Drug Research Laboratory, McGill University Health Center, Montreal, Canada., Radzioch D; Department of Human Genetics, McGill University, Montreal, Canada., Muanza TM; Department of Radiation Oncology, McGill University, Montreal, Canada; Segal Cancer Center, Jewish General Hospital, Montreal, Canada. Electronic address: tmuanza@yahoo.com.
Jazyk:	angličtina
Zdroj:	International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2015 Jun 01; Vol. 92 (2), pp. 399-406. Date of Electronic Publication: 2015 Mar 27.
DOI:	10.1016/j.ijrobp.2015.01.026
Abstrakt:	Purpose: ZRBA1 is a combi-molecule designed to induce DNA alkylating lesions and to block epidermal growth factor receptor (EGFR) TK domain. Inasmuch as ZRBA1 downregulates the EGFR TK-mediated antisurvival signaling and induces DNA damage, we postulated that it might be a radiosensitizer. The aim of this study was to further investigate the potentiating effect of ZRBA1 in combination with radiation and to elucidate the possible mechanisms of interaction between these 2 treatment modalities. Methods and Materials: The triple negative human breast MDA-MB-468 cancer cell line and mouse mammary cancer 4T1 cell line were used in this study. Clonogenic assay, Western blot analysis, and DNA damage analysis were performed at multiple time points after treatment. To confirm our in vitro findings, in vivo tumor growth delay assay was performed. Results: Our results show that a combination of ZRBA1 and radiation increases the radiation sensitivity of both cell lines significantly with a dose enhancement factor of 1.56, induces significant numbers of DNA strand breaks, prolongs higher DNA damage up to 24 hours after treatment, and significantly increases tumor growth delay in a syngeneic mouse model. Conclusions: Our data suggest that the higher efficacy of this combination could be partially due to increased DNA damage and delayed DNA repair process and to the inhibition of EGFR. The encouraging results of this combination demonstrated a significant improvement in treatment efficiency and therefore could be applicable in early clinical trial settings. (Copyright © 2015 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu